- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00328237
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
Treatment of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed by Single-Unit or Double-Unit Cord Blood Transplantation: A Phase II Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease.
Conditioning Regimen:
- Days -10 to -7: Fludarabine 30mg/m2/day IV
- Days -7 to -4: TBI 165 centigray BID
- Days -3 to -2: Cyclophosphamide 40mg/kg/day IV
Day 0: Infusion of Cord Blood Cells
Graft-vs-Host Disease Prophylaxis
- Day -1: Start tacrolimus 0.03mg/kg/day IV
- Day 0: Start MMF 7.5mg/kg IV BID
Studietype
Registrering
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Rocky Mountain Blood and Marrow Transplant Program
-
Underetterforsker:
- Michael Maris, MD
-
Underetterforsker:
- Scott Bearman, MD
-
Underetterforsker:
- Robert Rifkin, MD
-
Underetterforsker:
- Mark Brunvand, MD
-
Underetterforsker:
- Jeffrey Matous, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients must:
- Be between the ages of 18 and 49 years inclusive.
Have histologically proven hematologic malignancy and must meet accepted indications for allogeneic stem cell transplantation:
- Acute myeloid leukemia (AML): high-risk in first complete remission (CR), near first CR (< 20% marrow blasts after induction therapy), or beyond first remission.
- Acute lymphoblastic leukemia with high-risk features in first remission (Philadelphia chromosome positive or other similar high-risk features), near first CR (< 20% marrow blasts after induction therapy), or beyond first remission.
- Chronic myeloid leukemia: in chronic phase (CP) and have failed Gleevec or are intolerant and have signs of failing other treatments, or have history of accelerated or blast phases. Storage of autologous peripheral blood stem cells is recommended for this group for patients, particularly if in chronic phase.
- Non-Hodgkin's lymphoma: aggressive histology with relapsed or primary refractory disease and not eligible for autologous transplantation. Patients with low-grade histology must have either failed 2 or more lines of systemic chemotherapy including one rituximab-based regimen. Radioimmunotherapy will be considered the equivalent of one line of chemotherapy. Excluded if prior radiotherapy to chest or prior autologous transplantation.
- Myelodysplastic syndromes with International Prognostic Scoring System (IPSS) score of 1.5 or greater.
- Other hematological malignancies if approved by the pipeline meeting on a case by case basis. Must also be approved by principal investigator.
- Have no HLA-matched or 1-antigen mismatched related donors and no HLA-matched unrelated stem cell donors, or delays involved in performing a search are likely to be detrimental to the patient.
- Have an ECOG performance status of 0 or 1 at the time of transplant.
- Have major end organs (heart, lungs, liver, and kidneys) assessed and deemed adequate to withstand the effects of high-dose therapy planned for this protocol.
- Have given voluntary informed consent.
Exclusion Criteria:
Patients are ineligible for this protocol if they:
- Have a co-morbid medical condition, a psychiatric condition, or organ dysfunction that makes them at high-risk for treatment failure, for failed medical compliance, or for regimen-related toxicity from high-dose therapy.
Patients with any of the following will be excluded:
- Pulmonary: hemoglobin (Hb)-adjusted diffusing capacity of lung for carbon monoxide (DLCO) < 60%, forced expiratory volume in 1 second (FEV1) < 70% of predicted, or receive continuous supplemental oxygen;
- Cardiac: left ventricular ejection fraction (LVEF) < 50% or on any treatment for congestive heart failure;
- Renal: serum creatinine greater than 2.0 or calculated creatinine clearance < 50 cc/min;
- Liver: ALT, AST, or serum bilirubin > 1.5 x upper limit of normal (ULN). Any patient with elevated transaminases should have careful evaluation for the cause and liver biopsy may be required by the principle investigator. An elevated alkaline phosphatase should be fractionated and, if of liver origin, should be evaluated as for transaminases.
- Are female and are pregnant, lactating, or have a positive pregnancy test.
- Have a history of previous malignancy except for non-melanoma skin cancer and in-situ carcinoma of the cervix, unless the patient has been progression-free for > 5 years
- Are HIV positive
- Refractory malignancy: acute leukemia with greater than 30% blasts in bone marrow unless with untreated first relapse of AML or untreated myelodysplastic syndrome evolved to AML.
- Acute leukemia with greater than 1000 blasts/ul in peripheral blood.
- Uncontrolled central nervous system (CNS) leukemia or lymphoma.
- Prior autologous or allogeneic transplantation using a myeloablative regimen.
- Uncontrolled hypertension (systolic blood pressure [SBP] > 140, diastolic blood pressure [DBP] > 90) or hypertension requiring > 2 drugs for good control (SBP < 130, DBP < 90).
- Invasive mold infection that is uncontrolled or has received less than one month of antifungal therapy.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units
|
Sekundære resultatmål
Resultatmål |
---|
Evaluate safety as measured by day 100 treatment related mortality
|
Evaluate incidence of platelet engraftment
|
Evaluate incidences of acute and chronic graft-versus-host disease (GVHD)
|
Evaluate efficacy as measured by survival at 1 and 2 years after transplant
|
Evaluate chimerism from double cord transplants to determine source of long term engraftment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Peter McSweeney, MD, Colorado Blood Cancer Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Neoplasmer etter nettsted
- Benmargssykdommer
- Hematologiske sykdommer
- Myeloproliferative lidelser
- Leukemi, lymfoid
- Myelodysplastiske syndromer
- Hematologiske neoplasmer
- Leukemi
- Leukemi, myeloid
- Forløpercelle lymfoblastisk leukemi-lymfom
- Leukemi, myelogen, kronisk, BCR-ABL positiv
Andre studie-ID-numre
- RMBMT-149
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Akutt myeloid leukemi
-
University of PennsylvaniaAktiv, ikke rekrutterendeAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi, refraktær | Akutt myeloid leukemi, pediatriskForente stater
-
Betta Pharmaceuticals Co., Ltd.Har ikke rekruttert ennåAkutt Myeloid Leukemi LeukemiKina
-
Washington University School of MedicineTilbaketrukketRefraktær Akutt Myeloid Leukemi | Tilbakefallende akutt myeloid leukemiForente stater
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.AvsluttetAkutt myeloid leukemi | Refraktær Akutt Myeloid Leukemi | Tilbakefallende akutt myeloid leukemiForente stater
-
Xuzhou Medical UniversityRekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Xuzhou Medical UniversityRekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærKina
-
Bio-Path Holdings, Inc.RekrutteringAkutt myeloid leukemi, i tilbakefall | Akutt myeloid leukemi refraktærForente stater
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RekrutteringStudie av APG2575 enkeltmiddel og kombinasjon med terapi hos pasienter med tilbakefall/refraktær AMLMyeloid malignitet | Tilbakefallende/Refraktær Akutt Myeloid LeukemiKina
-
Beijing Boren HospitalRekrutteringAkutt myeloid leukemi | Refraktær Akutt Myeloid Leukemi | Tilbakefall leukemiKina
Kliniske studier på Cord Blood Transplant
-
MinYoung Kim, M.D.FullførtGlobal utviklingsforsinkelseKorea, Republikken
-
MinYoung Kim, M.D.Fullført
-
MinYoung Kim, M.D.Fullført
-
Bundang CHA HospitalTilbaketrukketCerebral pareseKorea, Republikken
-
Nanfang Hospital of Southern Medical UniversityUkjentSteroid-refraktær gastrointestinal akutt graft versus vertssykdomKina
-
Natera, Inc.TilbaketrukketHjertetransplantasjonssvikt og avvisning
-
Northwestern UniversityUniversity of Colorado, Denver; Mayo Clinic; The Methodist Hospital Research... og andre samarbeidspartnereFullført
-
University Health Network, TorontoUkjent
-
Paul Fortin, MDMusculoskeletal Transplant FoundationFullført
-
Thomas Klootwyk, MDSignature Biologics, LLC; KLM Solutions, LLCHar ikke rekruttert ennå